Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Cenix BioScience and Debiopharm Group Collaborate to Identify Predictive Biomarkers

May 23, 2013

LAUSANNE, Switzerland and DRESDEN, Germany, May 23, 2013 /PRNewswire/ –

Cenix BioScience, a leading preclinical contract research provider and technology
developer specialized in RNAi-, miRNA- and high content-driven pharmacology, and
Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of
companies with a focus on the development of prescription drugs that target unmet medical
needs, including oncology and companion diagnostics, today announced that they have signed
a research agreement to support Debiopharm in its ongoing efforts to develop novel
therapeutic drug candidates.

Under the research framework’s first project, Cenix will apply its leading expertise
in combining high throughput screening with high content assays in cultured human cells,
to identify predictive biomarkers for Debiopharm preclinical oncology candidates.
Multi-parametric microscopy-based readouts established by Cenix using the Definiens XD
image analysis platform will be used in a range of human cancer cell models to identify
genes and pathways that either enhance or suppress the drug’s therapeutic effects. As
such, the study represents another important illustration of Debiopharm’s ongoing drive to
integrate cutting edge technologies and powerful post-genomic strategies towards further
refining its personalized medicine approach towards the development of new therapeutics.

“We are very excited to launch this new relationship with Debiopharm, extending their
repertoire with what we consider to be some of the most strategically powerful cell-based
screening paradigms developed to date,” said Dr. Christophe Echeverri, CEO/CSO of Cenix
BioScience. “We deeply appreciate and are particularly gratified by this implied trust
from yet another world-class and forward-leaning drug development organization, who also
happens to be a long-standing expert in R&D outsourcing.”

“We look forward to working with Cenix, whose specialist expertise, longstanding
leadership and unrivaled track record in this field made them an ideal partner,” commented
Dr. Hiroaki Tanaka, Director of Personalized Medicine, Debiopharm. “The opportunity to
benefit from such depth of knowledge, experience and extensively validated capabilities is
considered as the most strategically important resource for preclinical biomarkers
discovery.”

About Cenix BioScience

With operations in Germany, Belgium and the U.S., Cenix BioScience conducts contract
research and develops new reagent technologies focused on a wide array of preclinical
cell-based and in vivo applications including RNAi-based gene silencing, miRNA modulation,
compound testing, advanced genomics analyses and high content screening to accelerate drug
discovery and development. Now in its 14th year, Cenix has built up leading scientific and
commercial track records, successfully advancing therapeutic programs for numerous top
industry and academic partners in a broad range of disease fields. This success,
illustrated by a high rate of repeat business from top clients, is anchored in the
consistent application of industrial best practices within fully customized, multi-staged
projects designed to offer maximal strategic value and accountability with carefully
minimized risk and full data transparency. For more information, please visit the
company’s web site: http://www.cenix.com

About Debiopharm Group(TM)

Debiopharm Group(TM) (Debiopharm) is a Swiss-based global biopharmaceutical group of
companies with a focus on the development of prescription drugs that target unmet medical
needs. The group in-licenses, develops and/or co-develops promising biological and small
molecule drug candidates having reached clinical development phases I, II or III, as well
as earlier stage candidates. It develops its products for global registration and maximum
commercial potential. The products are out-licensed to pharmaceutical partners for sales
and marketing. Debiopharm is also active in the field of companion diagnostics with a view
to progressing in the area of personalized medicine. Debiopharm independently funds the
worldwide development of all of its products while providing expertise in pre-clinical and
clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

For more information about Debiopharm Group(TM), please visit:

http://www.debiopharm.com

Cenix and the Cenix BioScience logo are registered trademarks owned by Cenix
BioScience GmbH.

Definiens XD and Definiens are registered trademarks owned by Definiens AG.

        Debiopharm S.A. Contact
        Beatrice Hirt
        Communication Coordinator
        bhirt@debiopharm.com
        Tel: +41-21-321-0111

        Additional Media Contacts
        In London
        Maitland
        Brian Hudspith
        Tel: +44(0)20-7379-5151
        bhudspith@maitland.co.uk

        In New York
        Russo Partners, LLC
        Martina Schwarzkopf, Ph.D.
        Account Executive
        Tel: +1-212-845-4292
        Fax: +1-212-845-4260
        martina.schwarzkopf@russopartnersllc.com

        Cenix EU Contact
        Dr. Christoph Sachse
        Director Cell-based Services
        Tel: +49-351-4173-0
        info@cenix.com

        Cenix USA Contact
        Dr. Sirid Kellermann
        Director of Marketing
        Tel: +1-650-996-9927
        kellermann@cenix.com

SOURCE The Debiopharm Group


Source: PR Newswire